II. Background
- No longer available (off market in U.S.) due to hepatotoxicity
- Listed for historical reasons only
III. Mechanism
IV. Indications: Non-Valvular Atrial Fibrillation
- Warfarin intolerant
- Patients with high risk of Intracranial Hemorrhage
V. Efficacy
- Advantages
- As effective as Warfarin with INR 2-3
- Ximelagartan does not require monitoring
- Ximelagartan has fewer bleeding complications
- Disadvantages
- Expensive
- Myocardial Ischemia risk
- Risk of severe liver toxicity
VI. Dosing
- Studies used fixed dose of 36 mg bid